Bob Kramer, Emergent BioSolutions CEO

Emer­gent nets an­oth­er man­u­fac­tur­ing deal, this time for Ridge­back­'s Ebo­la treat­ment

While Covid-19 and mon­key­pox cur­rent­ly dom­i­nate head­lines and so­cial health pri­or­i­ties, gov­ern­ment of­fi­cials aren’t for­get­ting about Ebo­la and its po­ten­tial for se­ri­ous out­breaks.

Emer­gent BioSo­lu­tion inked an agree­ment last week with Ridge­back Bio­ther­a­peu­tics in a col­lab­o­ra­tion to ex­pand the avail­abil­i­ty of Ebo­la treat­ment Eban­ga. Un­der the deal, Emer­gent will be re­spon­si­ble for the man­u­fac­tur­ing, sale and dis­tri­b­u­tion of Eban­ga in the US and Cana­da. Ridge­back Bio for its part will serve as the glob­al part­ner for the drug and en­sure it re­mains avail­able to pa­tients in en­dem­ic coun­tries free of charge through its com­pas­sion­ate use pro­gram.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.